MJ33 (lithium salt)
目录号 : GC10645An inhibitor of the PLA2 activity of Prdx6
Cas No.:1007476-63-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: ≥95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
MJ33 is an inhibitor of the acidic, calcium-independent (ai)PLA2 activity of Prdx6.
Peroxiredoxin-6 (Prdx6), a bifunctional enzyme, has both non-selenium glutathione peroxidase and phospholipase A2 (PLA2) activities. The PLA2 activity of Prdx6 is calcium-independent, functions optimally in acidic conditions, and facilitates the intracellular processing of surfactant lipids, such as dipalmitoylphosphatidylcholine.
In vitro: MJ33 was found to be specifically inhibit the aiPLA2 activity of the protein. Moreover, the Ca2+-independent PLA2 activity of phosphorylated rat Prdx6 could be abolished by the treatment of either MJ33 or surfactant protein A (SP-A), known inhibitors of aiPLA2 activity. Further supporting the results with intact cells, recombinant Prdx6 was phosphorylated in vitro by ERK and p38, but not by JNK. Phosphorylation in vitro led to a great increase in PLA2 activity that was Ca2+-independent and ould be inhibited by both MJ33 and by SP-A, which was similar to native lung enzyme [1].
In vivo: A previous study evaluated the effect of MJ33 on manifestations of acute lung injury. Results showed that MJ33 could inhibit reactive oxygen species generation by lungs when measured LPS treatment. LPS at either a low or high dose significantly increased lung infiltration with inflammatory cells, secretion of proinflammatory cytokines, expression of lung vascular cell adhesion molecule, lung permeability, tissue lipid peroxidation, tissue protein oxidation, and activation of NF-κB. MJ33, given either concurrently or 2 h subsequent to LPS, was able to significantly reduce all of these measured parameters [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Wu, Y. ,Feinstein, S.I.,Manevich, Y., et al. Mitogen-activated protein kinase-mediated phosphorylation of peroxiredoxin 6 regulates its phospholipase A2 activity. Biochem. 419(3), 669-679 (2009).
[2] Lee I, Dodia C, Chatterjee S, Feinstein SI, Fisher AB. Protection against LPS-induced acute lung injury by a mechanism-based inhibitor of NADPH oxidase (type 2). Am J Physiol Lung Cell Mol Physiol. 2014 Apr 1;306(7):L635-44.
| Cas No. | 1007476-63-2 | SDF | |
| 化学名 | mono[1-[(hexadecyloxy)methyl]-2-(2,2,2-trifluoroethoxy)ethyl] monomethyl ester phosphoric acid, monolithium salt | ||
| Canonical SMILES | O=P(OC)([O-])OC(COCC(F)(F)F)COCCCCCCCCCCCCCCCC.[Li+] | ||
| 分子式 | C22H43F3O6P • Li | 分子量 | 498.5 |
| 溶解度 | ≤2mg/ml in ethanol;0.25mg/ml in DMSO;0.5mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.006 mL | 10.0301 mL | 20.0602 mL |
| 5 mM | 0.4012 mL | 2.006 mL | 4.012 mL |
| 10 mM | 0.2006 mL | 1.003 mL | 2.006 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。